Navigation Links
An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
Date:1/21/2009

Stelara Will Earn Decision Resources' Clinical Gold-Standard for Psoriasis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral agent for the treatment of moderate to severe psoriasis that demonstrates improved efficacy and lasting remission when compared with Amgen/Wyeth/Takeda's Enbrel would earn a higher patient share in the United States (20 percent) than in Europe (10 percent), according to surveyed U.S. and European dermatologists. Although the parenteral route of administration has not handicapped the performance of biological agents in the psoriasis market, oral therapies are still preferred by dermatologists for their convenience and the assumption that they will be priced lower than biological agents.

The new report entitled Psoriasis: Physicians Identify Key Differentiating Product Features in Crowded Market for Moderate to Severe Psoriasis finds that surveyed dermatologists indicate that a therapy's effect on psoriatic plaques at 10 or 12 weeks is the attribute that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that emerging therapies, Centocor/Janssen-Cilag's Stelara, Abbott's ABT-874 and UCB/Otsuka's Cimzia, have advantages in this attribute over Enbrel, the psoriasis market sales leader. Following its likely approval in 2009 for moderate to severe psoriasis, Stelara will earn Decision Resources' proprietary clinical gold-standard for psoriasis from 2012 to 2017.

"Stelara's unique and most significant advantage among therapies for moderate to severe psoriasis is its effect on lasting remission," said Decision Resources Analyst Joanna Kim. "Interviewed experts believe that Stelara's notable efficacy, combined with its 12-week dosing interval, will position this agent to compete directly with agents in the TNF-alpha inhibitors drug class and will capture significant use as a first-line biologic in the psoriasis market."

About the Report

Psoriasis: Physicians Identify Key Differentiating Product Features in Crowded Market for Moderate to Severe Psoriasis is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. MassMutual Agent Honored by Insurance Industry for Extraordinary Service to Client
5. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
6. ABR-Affinity BioReagents Expands 100% Quality Guarantee
7. Inside job: new radioactive agents for colon cancer work inside cells
8. ABR -- Affinity BioReagents Announces Launch of New Website
9. The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing
10. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
11. Imagentix Offers Extension of Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 ... ... the female reproductive tract in which the endometrial lining of the uterus ... inflammation and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 24, 2017 , ... Technique, technique, technique – with a dash of common ... strength training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional ... Dr. Chang says. “Improper technique in lifting anything heavy or an attempt to lift ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Allegheny ... to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at West ... available in western Pennsylvania for women suffering from pregnancy-related depression. Construction of the ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a ... KLAS category winner, has named Daniel P. Bullington as chief technology officer. , ... platform and product offerings,” says Justin Neece, president. “Daniel is an excellent fit ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Radiology has ... unfortunately its costs have also spiraled to the number ... sent to radiology than ever before as the most ... For a patient with lower back pain an MRI ... anatomical reason for pain, resulting in entirely different treatment ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
Breaking Medicine Technology: